Priority for Pediatric Cures Act
- Sponsor
- Rep. Bilirakis, Gus M. [R-FL-12]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 14, 2026
Bottom line
This bill ensures the continuation of a key incentive program designed to encourage pharmaceutical companies to develop treatments for rare diseases affecting children.
What it actually does
The bill permanently extends the Food and Drug Administration's (FDA) authority to award priority review vouchers (PRVs) for rare pediatric disease products by removing the sunset clause from the relevant section of the Federal Food, Drug, and Cosmetic Act. This means that drug developers who successfully bring a new drug for a rare pediatric disease to market would continue to be eligible for a voucher that can be used to expedite the review of another product.
Proponents argue
Proponents argue that the Rare Pediatric Disease Priority Review Voucher program is a vital incentive for pharmaceutical companies to invest in the development of treatments for conditions that affect small patient populations, which might otherwise be neglected due to limited commercial viability. They contend that extending this authority permanently will provide certainty to developers and ultimately lead to more cures and therapies for children with rare diseases.
Opponents contend
Opponents, if any, might argue that while the intent is good, the PRV program itself may not be the most efficient or cost-effective mechanism for incentivizing drug development, potentially leading to inflated drug prices or diverting FDA resources. However, specific organized opposition to the extension of this particular program is generally uncommon given its focus on pediatric rare diseases.
The bill text is exceptionally short and can be read in under a minute, making it highly accessible for any reader.
Section 2
Permanent Extension of Rare Pediatric Disease Priority Review Voucher Program
This section amends Section 529(b) of the Federal Food, Drug, and Cosmetic Act by removing paragraph (5). Paragraph (5) currently specifies a sunset date for the Rare Pediatric Disease Priority Review Voucher program, meaning the authority to award these vouchers would expire. By striking this paragraph, the bill makes the program permanent, allowing the FDA to continue awarding these vouchers indefinitely.
Supporters argue
Supporters argue that the permanent extension provides long-term certainty for drug developers, encouraging sustained investment in a challenging and often unprofitable area of drug development. This stability is crucial for planning multi-year research and clinical trials.
Critics contend
No specific organized opposition is typically raised against the permanent extension of this particular program, as the underlying goal of incentivizing pediatric rare disease drug development is widely supported. Potential critics of the broader PRV program might raise concerns about its overall effectiveness or market distortions, but not necessarily against its permanence.
Tradeoffs
The primary tension involves balancing the need for incentives to develop drugs for small patient populations against potential concerns about the efficiency of the voucher system or its impact on the FDA's review process. However, the consensus generally leans towards the benefits for rare pediatric diseases.